title: [Cerebral amyloid angiopathy--an update].
abstract: Cerebral amyloid angiopathy (CAA) belongs to the group of amyloidoses and is characterised by the deposition and accumulation of beta-amyloid (Aβ) in small arterial vessels of the brain. Hereditary forms of CAA exist but sporadic CAA is much more frequent. Deposition of Aβ induces degenerative changes of the cerebral vascular system (thickening of the vessel wall, constriction of vascular lumen, microaneurysms, dissection) that trigger the development of the typical clinical presentation of CAA, that is spontaneous intracerebral haemorrhage. Apart from haemorrhages, also cerebral ischaemia, transient neurological symptoms, leukencephalopathy as well as cognitive decline and dementia can occur in association with CAA. The definite diagnosis of CAA is only possible by means of pathological examination, even though neuroimaging and clinical findings allow the diagnosis of a probable CAA. Currently, no specific causal therapy exists. Although CAA is located in the range of neurological diseases psychiatric symptoms might occur. In the review, we discuss epidemiological, pathogenetic, clinical and diagnostic aspects and possible psychiatric implications of CAA.
authors.affiliation: Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm, Ulm, Germany. maximilian.gahr@uni-ulm.de
authors.forename: M
authors.initials: M
authors.lastname: Gahr
authors.forename: D A
authors.initials: DA
authors.lastname: Nowak
authors.forename: B J
authors.initials: BJ
authors.lastname: Connemann
authors.forename: C
authors.initials: C
authors.lastname: Schönfeldt-Lecuona
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism; D016657:Cerebral Amyloid Angiopathy / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000523:psychology / Q000628:therapy; D003071:Cognition / Q000502:physiology; D006801:Humans; D059906:Neuroimaging; D012307:Risk Factors
chemical_list: D016229:Amyloid beta-Peptides